Form 10-Q · Quarterly report
Moderna 10-Q, filed Jul 31, 2026
- Filed
- CIK
- 0001682852
- Accession no.
- 0001682852-26-000150
Summary
Moderna reported a second-quarter 2026 net loss of $782 million, narrower than the $825 million loss a year earlier, on total revenue of $145 million, while its first-half net loss widened to $2.13 billion from $1.80 billion. The company said it had four approved products as of June 30, 2026 and 26 development candidates across 36 clinical-stage programs.
Key points
- First-half net loss widened to $2.13 billion from $1.80 billion a year earlier, with second-quarter net loss of $782 million versus $825 million.
- Second-quarter total revenue was $145 million against $142 million a year earlier; net product sales fell to $94 million from $114 million.
- Second-quarter research and development expense was $651 million, down from $700 million.
- Moderna listed four approved products as of June 30, 2026 — Spikevax, mNEXSPIKE, mRESVIA and mCOMBRIAX, the flu/COVID combination vaccine approved in Europe for people 50 and older — and said it has 26 development candidates across 36 clinical programs.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 29 Item 3. Quantitative and Qualitative Disclosures about Market Risk 38 Item 4. Controls and Procedures 38 PART II. Item 1. Legal Proceedings 39 Item 1A. Risk Factors 39 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 39 Item 5. Other Information 40 Item 6. Exhibits 41 SIGNATURES 42 Table of Contents Item 1. Financial Statements MODERNA, INC. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.